DaltonTx Raises £4 Million Seed Financing to Build the Intelligence Backbone of Drug Discovery

DaltonTx, a collaborative intelligence platform redefining how technology

powers drug discovery, led by Dr. Garry Pairaudeau, Dr. Anthony Bradley, Professor Charlotte Deane MBE, Adrian Rossall, and others, has announced its exit from stealth and the completion of a £4 million seed financing from redalpine, IQ Capital Partners, and Seedcamp, and support from Oxford University Innovation.

DaltonTx is an adaptive AI platform for drug discovery that integrates seamlessly into pharma, biotech, and CRO workflows, giving teams immediate access to AI-enabled discovery without years of internal development. Unlike traditional predictive tools, DaltonTx powers the full discovery process, data, modeling, molecular design, synthesis, and decision-making, while continuously learning from every scientist, model, and experiment.

Co-founded by leaders from AstraZeneca, Exscientia, and the University of Oxford, DaltonTx combines deep expertise in drug discovery, machine learning, and software engineering to transform how medicines are developed.

DaltonTx’s platform is built to support both small molecules and biologics, enabling it to handle the most complex R&D pipelines. It fosters collaborative intelligence by combining human expertise with an adaptive engine that iterates and learns, allowing scientists and AI to work together seamlessly. Based in London’s King’s Cross, the company sits at the intersection of engineering, AI, and drug discovery.